ArticleInternational journal of molecular sciences2022
Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 82 citations in OpenAlex.
- Article
- Ranalexin-1G: A Promising Antimicrobial Peptide Targeting Virulence and Host-Pathogen Interactions inAntibiotics (Basel, Switzerland) · 2026Article
- Identification and Optimization of a Truncated Hs-1-Derived Antimicrobial Peptide for Enhanced Broad-Spectrum Antiviral Activity.ChemMedChem · 2026Article
- Article
- A Comprehensive Review on Non-natural Amino Acid-based Modifications in Antibacterial Peptides.Mini reviews in medicinal chemistry · 2026Review
- Probing Guanidino Pendant or Bridged Groups in Cyclic Antimicrobial Peptides Derived from Temporin L: A Strategy to Improve Efficacy against Gram-Negative Bacteria.Journal of medicinal chemistry · 2025Article
- Genome-Guided Identification and Characterisation of Broad-Spectrum Antimicrobial Compounds of Bacillus velezensis Strain PD9 Isolated from Stingless Bee Propolis.Probiotics and antimicrobial proteins · 2025Article
- Bicyclic temporin L peptide inhibitors targeting the SARS-CoV-2 main protease: design, synthesis,RSC medicinal chemistry · 2025Article
- Next-generation antiviral peptides: AI-driven design, translational delivery platforms, and future therapeutic directions.Virus research · 2025Review
- Structure-Function Insights into Frog Skin Peptides Reveal Potent Inhibition of West Nile Virus Entry.International journal of molecular sciences · 2025Article
- Structure-Guided Temporin L Analogs Development to Inhibit the Main Protease of SARS-CoV‑2.ACS medicinal chemistry letters · 2025Article
- Antimicrobial Peptides Against Arboviruses: Mechanisms, Challenges, and Future Directions.Probiotics and antimicrobial proteins · 2025Review
- Membrane-Targeting Antivirals.International journal of molecular sciences · 2025Review
- Expanding the Antiviral Spectrum of Scorpion-Derived Peptides Against Toscana Virus and Schmallenberg Virus.Pathogens (Basel, Switzerland) · 2025Article
- Advances in the Role of Antimicrobial Peptides in the Management of Sexually Transmitted Infections.Journal of clinical laboratory analysis · 2025Review
- Frog Skin Peptides Hylin-a1, AR-23, and RV-23: Promising Tools Against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Revisiting the potential of natural antimicrobial peptides against emerging respiratory viral disease: a review.3 Biotech · 2025Review
- Outer membrane vesicles fromFrontiers in molecular biosciences · 2025Article
- Progress in the classification, optimization, activity, and application of antimicrobial peptides.Frontiers in microbiology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
The COVID-19 pandemic has evidenced the urgent need for the discovery of broad-spectrum antiviral therapies that could be deployed in the case of future emergence of novel viral threats, as well as to back up current therapeutic options in the case of drug resistance development. Most current antivirals are directed to inhibit specific viruses since these therapeutic molecules are designed to act on a specific viral target with the objective of interfering with a precise step in the replication cycle. Therefore, antimicrobial peptides (AMPs) have been identified as promising antiviral agents that could help to overcome this limitation and provide compounds able to act on more than a single viral family. We evaluated the antiviral activity of an amphibian peptide known for its strong antimicrobial activity against both Gram-positive and Gram-negative bacteria, namely Temporin L (TL). Previous studies have revealed that TL is endowed with widespread antimicrobial activity and possesses marked haemolytic activity. Therefore, we analyzed TL and a previously identified TL derivative (Pro
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.